2011

How much money the pharmaceutical industry spends on Internet marketing, direct-to-consumer advertising, and physician detailing are always topics of interest and 2010 was no exception. 2010 was, however, a turning point in bringing more attention to payments made to physicians for speaking, consulting, and research.

Opening the Door to FDA-Compliant Branded Tweets: Deck.ly has enormous potential for pharmaceutical marketers who have been chaffing at the bit to post meaningful branded messages via Twitter but who have been stymied by lack of guidance from FDA regarding how to provide fair balance within the 140-character limit of Twitter.

Economic Experts Disagree Wildly on How Much It Costs to Bring a New Drug to Market. How is it that the Tufts estimate is at least 14 TIMES the London School of Economics and Political Science (LSEPS) estimate? 'Make no mistake,' said Tufts. 'Tufts CSDD will vigorously defend the scholarship, integrity, and validity of all its published research studies.'

This article focuses on Adobe Connect for eDetailing, a specific collaboration between Adobe and ConnectSolutions, a leading provider of private cloud deployments of web conferencing and collaboration solutions.

Looming Challenges Cloud Implementation. This article reviews the strategic implications of the Sunshine Act and also presents highlights of the draft regulations rule released by the Centers for Medicare and Medicaid Services on December 15, 2011.

Pharma marketers save a bundle repurposing videos for Youtube. They save even more money by hiring real patients to play themselves in these videos! Patients are natural method actors, having actually experienced what they portray. But they are prone to over emote!

The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.

Allergan, Eli Lilly, Johnson and Johnson, Novartis, Pfizer, Novo, and Sanofi-Aventis filed a 'citizen petition' with the FDA, urging the agency to 'establish comprehensive, clear and binding regulations to guide the industry' in communicating off-label drug information to physicians and payers. Although the words 'Internet' and 'Social Media' are not mentioned in the petition, it is likely to hold up social media guidelines regarding 'unsolicited requests' that were promised as the first in a series of FDA guidelines.

Rules for Third-Party Engagement in Patient/Physician Social Networks. A Social Media Policy is not just an agreement that users must abide by. More importantly, it is a PROMISE to users from site owners/sponsors concerning how they will protect or attempt to protect user-generated content, personal conversations, interactions, and engagements with third-parties on the site. These policies should comply with as-yet-to-be-determined, universally accepted 'fair social media practice principles.'

Boehringer-Ingelheim (BI) stands out in its attempt to stand out from the social(ist) cookie-cutter crowd of pharma FB pages. Shows what you can do with dedicated resources and creativity.